Last reviewed · How we verify
Diluent
At a glance
| Generic name | Diluent |
|---|---|
| Also known as | diluent(0.5% Nacl,0.25% NaHCO3,50% glycerin,& 0.4% phenol), Normal saline |
| Sponsor | University Health Network, Toronto |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Safety Evaluation of PfSPZ Vaccine in Pregnant Women in Mali (MalVIP1) (PHASE1)
- L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML (PHASE2, PHASE3)
- Safety, Tolerability and Immunogenicity of a Maternal Respiratory Syncytial Virus (RSV) Vaccine (MKK900) in Healthy Adult Women (PHASE1)
- Exenatide for Smoking Cessation and Prevention of Weight Gain (PHASE2)
- A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA) (PHASE3)
- A Study to Test the Effects of Nezavist at Different Doses in Healthy Adults (PHASE1)
- Prehospital Pulse-dose Glucocorticoid in Patients With ST-segment Elevation Myocardial Infarction 2 - The PULSE-MI 2 Trial (PHASE3)
- pH1N1 Blinded Challenge Study (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Diluent CI brief — competitive landscape report
- Diluent updates RSS · CI watch RSS
- University Health Network, Toronto portfolio CI